RECRUITINGOBSERVATIONAL

Cohort of Patients With Systemic Granulomatosis and Associated Biological Collection

Cohort of Patients With Systemic Granulomatosis (Sarcoidosis and Other Systemic Granulomatoses) and Associated Biological Collection GRAMI-BIO Study

About This Trial

The GRAMI-BIO study is a prospective single-centre cohort study to recruit 150 patients followed up in the the Bordeaux University Hospital. The total duration of the GRAMI-BIO study is ten years (five years of inclusion with five years of follow-up): Consecutive inclusion of patients meeting the definition of systemic granulomatosis. The main objective of this cohort is to describe to clinical progression of systemic granulomatosis and to collect blood fraction samples (serum bank, plasma bank, urine bank, DNA bank) from subjects participating in the cohort.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients aged 18 or over - Patients with systemic granulomatosis (diagnosis proven by anatomopathological sampling) at diagnosis. - Persons affiliated to or benefiting from a social security scheme. - Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). Who Should NOT Join This Trial: - Patients infected with human weakened immune system virus (HIV), Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) - Pregnant or breast-feeding women - Patients already receiving specific treatment for systemic granulomatosis - Persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Patients aged 18 or over * Patients with systemic granulomatosis (diagnosis proven by anatomopathological sampling) at diagnosis. * Persons affiliated to or benefiting from a social security scheme. * Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). Exclusion Criteria: * Patients infected with human immunodeficiency virus (HIV), Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) * Pregnant or breast-feeding women * Patients already receiving specific treatment for systemic granulomatosis * Persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent.

Treatments Being Tested

BIOLOGICAL

blood sample

30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

BIOLOGICAL

urine sample

10 ml

Locations (1)

CHU de Bordeaux - service de Médecine Interne et Immunologie Clinique

Bordeaux, France